市場調查報告書
商品編碼
1423556
2030 年Gabapentin市場預測:按產品類型、給藥途徑、購買型態、應用、最終用戶和地區進行的全球分析Gabapentin Market Forecasts to 2030 - Global Analysis By Product (Tablet, Capsule and Other Products), Type (Generic, Branded and Other Types), Route of Administration, Mode of Purchase, Application, End User and By Geography |
根據Stratistics MRC的數據,2023年全球Gabapentin市場規模為21.7152億美元,預計到2030年將達到35.6761億美元,預測期內複合年成長率為7.4%。
Gabapentin是一種模仿神經傳導物質γ-胺基丁酸(GABA)的藥物,主要用作抗驚厥藥物和緩解神經病變疼痛。它經美國食品藥物管理局(FDA)核准,用於治療多種疾病,包括癲癇、帶狀皰疹後遺症神經痛和不寧腿症候群。由於其在治療神經系統疾病和慢性疼痛方面的多功能性,它已成為現代醫學的寶貴資產。
報告稱,Gabapentin在2020年美國處方藥中排名第6。 2020年,美國將開出5,700萬張處方箋。
提高意識
醫療保健專業人員和患者越來越了解該藥物在治療各種神經系統疾病和神經性疼痛方面的有效性。GabapentinGabapentin。此外,以患者為中心的醫療保健正在不斷發展並鼓勵明智的決策,從而成為推動該市場的關鍵因素。
誤用和濫用
Gabapentin的濫用包括服用超過處方量、未經處方箋使用以及與其他物質一起使用以增強所需效果。Gabapentin濫用可引起多種副作用,包括頭暈、鎮靜、失去協調性、視力模糊和認知障礙。此外,長期誤用或濫用Gabapentin後突然停藥可能會導致焦慮、失眠和煩躁等戒斷症狀,這將嚴重阻礙該市場的擴張。
擴大遠端醫療服務
遠端醫療服務的擴展將有助於醫療保健,並對Gabapentin的獲取產生積極影響,使需要治療神經系統疾病和神經性疼痛的患者能夠輕鬆使用該藥物。遠端醫療允許醫療保健提供者遠端進行諮詢、開藥和監控患者狀況。此外,遠端醫療使醫療保健專業人員能夠遠端監控患者、快速解決問題並最佳化藥物管理,這正在推動這個市場。
副作用和耐受性
副作用的普遍存在給醫療保健提供者帶來了平衡Gabapentin的治療益處及其潛在缺點的挑戰。患者特定因素,例如年齡、潛在疾病和合併用藥,可能會影響副作用的可能性和嚴重程度。此外,副作用的存在阻礙了市場成長,因為它們可能需要額外的醫療干預措施,從而增加醫療成本和資源利用率。
COVID-19 的影響
COVID-19大流行對Gabapentin市場產生了一些負面影響。供應鏈中斷、封鎖措施和醫療保健優先事項的轉變共同為Gabapentin的生產、分銷和消費帶來了挑戰。經濟不確定性和醫療保健系統的財務壓力可能會推動成本降低並影響Gabapentin的承受能力。此外,就診醫療機構的患者數量減少可能會導致新處方和重複處方的減少,從而影響整體市場需求。
膠囊細分市場預計將在預測期內成為最大的細分市場
據估計,膠囊佔最大佔有率。這些是治療神經系統疾病和神經性疼痛的廣泛處方藥物,可有效治療帶狀皰疹後遺症神經痛神經病變和糖尿病神經病變等疾病。研究和開發計劃、監管核准和策略聯盟等因素影響市場動態。此外,對創新、安全性和可近性的關注仍然是更廣泛的製藥市場的重要貢獻者,並推動該領域的成長。
預計腸外藥物領域在預測期內複合年成長率最高
預計腸外用藥在預測期內的複合年成長率最高,因為它具有明顯的優勢,特別是在口服攝入困難的情況下,例如噁心、嘔吐和吞嚥困難的患者。這種給藥方法提高了治療依從性,並確保患者準確地接受處方劑量。此外,Gabapentin的腸胃外製劑為需要快速起效和精確劑量控制的患者提供了有效的替代方案,推動了該領域的成長。
由於北美在治療神經系統疾病和神經性疼痛的藥物市場中佔有重要地位,因此在預測期內獲得了最大的市場佔有率。輝瑞公司、梯瓦製藥有限公司、Glenmark 製藥有限公司和 Cipla USA Inc. 等主要市場是治療癲癇、帶狀皰疹後遺症神經痛和糖尿病神經病變等疾病的核心。此外,美國食品藥物管理局(FDA) 和加拿大衛生署等法律規範機構確保遵守安全標準並在該地區有效分銷。
由於歐洲在控制癲癇、帶狀皰疹後遺症神經痛和糖尿病神經病變等疾病方面的有效性,預計在預測期內將顯示出最高的複合年成長率。製藥公司從事製造和行銷活動,以滿足對Gabapentin不斷成長的需求,為歐洲與神經系統疾病作鬥爭的人們提供有效的解決方案。此外,神經系統疾病盛行率上升、人口老化以及慢性疼痛管理意識的提高等因素正在推動該地區的擴張。
According to Stratistics MRC, the Global Gabapentin Market is accounted for $2,171.52 million in 2023 and is expected to reach $3,567.61 million by 2030 growing at a CAGR of 7.4% during the forecast period. Gabapentin is a pharmaceutical compound used primarily as an anticonvulsant and to alleviate neuropathic pain which mimic the neurotransmitter gamma-aminobutyric acid (GABA). It is approved by the U.S. Food and Drug Administration (FDA), and is employed in the treatment of various medical conditions, including epilepsy, postherpetic neuralgia, and restless legs syndrome. The drug's versatility in addressing neurological disorders and chronic pain has made it a valuable asset in modern medicine.
According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020.
Increase in awareness
Healthcare professionals and patients are becoming more informed about the drug's efficacy in managing various neurological disorders and neuropathic pain conditions. Physicians are increasingly prescribing Gabapentin based on a deeper understanding of its mechanisms of action and the diverse range of conditions it can effectively address. In addition, the evolving landscape of patient-centered healthcare encourages informed decision-making, making awareness a crucial factor in driving this market.
Misuse and abuse
Gabapentin misuse can involve taking higher doses than prescribed, using it without a prescription, or combining it with other substances to intensify the desired effects. Abuse of gabapentin can result in various adverse effects, including dizziness, sedation, impaired coordination, blurred vision, and cognitive difficulties. Furthermore, abrupt discontinuation of gabapentin after prolonged misuse or abuse can result in withdrawal symptoms such as anxiety, insomnia, and restlessness, significantly hampering this market expansion.
Telehealth expansion
The expansion of telehealth services serves healthcare and positively impacts the accessibility of this medication by transforming easy delivery for individuals requiring gabapentin for neurological disorders and neuropathic pain. Telehealth allows healthcare providers to conduct remote consultations, prescribe medications, and monitor patients' conditions from a distance. Further, telehealth enables healthcare professionals to monitor patients remotely, address concerns promptly, and optimize medication management, which is propelling this market
Side effects and tolerance
The prevalence of side effects poses challenges for healthcare providers in balancing the therapeutic benefits of Gabapentin with its potential drawbacks. Patient-specific factors, such as age, underlying health conditions, and concurrent medications, can influence the likelihood and severity of side effects. Moreover, the presence of side effects may necessitate additional medical interventions, contributing to healthcare costs and resource utilization and thereby hindering market growth.
Covid-19 Impact
The COVID-19 pandemic has had several negative impacts on the Gabapentin market. Supply chain disruptions, lockdown measures, and shifts in healthcare priorities have collectively contributed to challenges in the production, distribution, and consumption of gabapentin. Economic uncertainties and financial strains on healthcare systems have prompted cost-cutting measures, potentially influencing the affordability of Gabapentin. Moreover, reduced patient visits to healthcare providers may have led to a decline in new prescriptions and refills, affecting overall market demand.
The capsule segment is expected to be the largest during the forecast period
The capsule segment is estimated to hold the largest share. These are pharmaceutical products widely prescribed for neurological disorders and neuropathic pain that are efficient in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Factors such as research and development initiatives, regulatory approvals, and strategic collaborations influence market dynamics. Furthermore, a focus on innovation, safety, and accessibility continues to be a vital contributor to the broader pharmaceutical market, driving this segment's growth.
The parenteral segment is expected to have the highest CAGR during the forecast period
The parenteral segment is anticipated to have highest CAGR during the forecast period due to distinct advantages, particularly in situations where oral intake may be challenging, such as for patients experiencing nausea, vomiting, or those with difficulty swallowing. This mode of delivery enhances treatment compliance and ensures patients receive the prescribed dosage accurately. Additionally, for individuals requiring rapid onset of action or precise dosage control, parenteral formulations of gabapentin provide an effective alternative, boosting this segment's expansion.
North America commanded the largest market share during the extrapolated period owing to its significant presence in the pharmaceutical landscape, addressing neurological disorders and neuropathic pain. Key markets such as Pfizer Inc., Teva Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, and Cipla USA Inc. have become cornerstones in the management of conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Furthermore, regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensures compliance with safety standards and effective distribution in this region.
Europe is expected to witness highest CAGR over the projection period, owing to its efficacy in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Pharmaceutical companies engage in manufacturing and marketing activities to meet the increasing demand for Gabapentin, aiming to provide effective solutions for individuals grappling with neurological conditions in Europe. In addition, factors such as the rising prevalence of neurological disorders, an aging population, and an increased awareness of chronic pain management are boosting this region's expansion.
Key players in the market
Some of the key players in the Gabapentin Market include Amneal Pharmaceuticals LLC., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Marksans Pharma, Novartis AG, Alkem Labs, Jiangsu Nhwa Pharmaceutical Co., Ltd, Aurobindo Pharma, Apotex Inc, Viatris Inc, Arbor Pharmaceuticals, LLC, Pfizer Inc, Teva Pharmaceuticals Ltd, Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC and Cipla USA, Inc.
In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
In October 2023, Zydus Lifesciences Company and Sun Pharmaceutical Industries Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.
In January 2023, Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment in equity value.